These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10520615)

  • 41. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections.
    Harel Z; Johnson CC; Gold MA; Cromer B; Peterson E; Burkman R; Stager M; Brown R; Bruner A; Coupey S; Hertweck P; Bone H; Wolter K; Nelson A; Marshall S; Bachrach LK
    Contraception; 2010 Apr; 81(4):281-91. PubMed ID: 20227543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Administration of depot medroxyprogesterone acetate on the day of mifepristone for medical abortion: a pilot study.
    Sonalkar S; McClusky J; Hou MY; Borgatta L
    Contraception; 2015 Feb; 91(2):174-7. PubMed ID: 25481376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone mineral density in women using depot medroxyprogesterone acetate for contraception.
    Scholes D; Lacroix AZ; Ott SM; Ichikawa LE; Barlow WE
    Obstet Gynecol; 1999 Feb; 93(2):233-8. PubMed ID: 9932562
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors Affecting Continued Use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): A Secondary Analysis of a 1-Year Randomized Trial in Malawi.
    Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Santo LD; Ngwira B
    Glob Health Sci Pract; 2019 Mar; 7(1):54-65. PubMed ID: 30894394
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term contraception with Depo-Provera: a clinical evaluation.
    Mukherjea M; Mukherjee P; Biswas R
    Int J Fertil; 1980; 25(2):122-6. PubMed ID: 6117526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Once-a-month injectable contraceptives: efficacy and reasons for discontinuation.
    Koetsawang S
    Contraception; 1994 Apr; 49(4):387-98. PubMed ID: 8013221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report.
    Contraception; 1983 Jul; 28(1):1-20. PubMed ID: 6226488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of hormonal contraception on bone mineral density after 24 months of use.
    Berenson AB; Breitkopf CR; Grady JJ; Rickert VI; Thomas A
    Obstet Gynecol; 2004 May; 103(5 Pt 1):899-906. PubMed ID: 15121563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Depo Now: preventing unintended pregnancies among adolescents and young adults.
    Rickert VI; Tiezzi L; Lipshutz J; León J; Vaughan RD; Westhoff C
    J Adolesc Health; 2007 Jan; 40(1):22-8. PubMed ID: 17185202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
    Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L
    Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. While women await surgery for type I endometrial cancer, depot medroxyprogesterone acetate reduces tumor glandular cellularity.
    Fiascone S; Danilack VA; Kao MJ; Cohen M; Singh K; Kalife E; Luis C; Lokich E; DiSilvestro P; Robison K
    Am J Obstet Gynecol; 2018 Oct; 219(4):381.e1-381.e10. PubMed ID: 30063901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of Early Discontinuation of Effective Contraception by Teens at High Risk of Pregnancy.
    Maslyanskaya S; Coupey SM; Chhabra R; Khan UI
    J Pediatr Adolesc Gynecol; 2016 Jun; 29(3):269-75. PubMed ID: 26526036
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaginal bleeding patterns in women using once-a-month injectable contraceptives.
    Fraser IS
    Contraception; 1994 Apr; 49(4):399-420. PubMed ID: 8013222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors associated with provision of depot medroxyprogesterone acetate to adolescents by US health care providers.
    Ermias Y; Morgan IA; Curtis KM; Whiteman MK; Horton LG; Zapata LB
    Contraception; 2019 May; 99(5):300-305. PubMed ID: 30763582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. No bones about it--depot medroxyprogesterone acetate remains an excellent contraceptive option for adolescents.
    Rager KM
    J Pediatr Adolesc Gynecol; 2005 Jun; 18(3):187-8. PubMed ID: 15970254
    [No Abstract]   [Full Text] [Related]  

  • 57. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of Long-Acting Reversible Contraception (LARC) and the Depo-Provera Shot in Adolescents.
    Itriyeva K
    Curr Probl Pediatr Adolesc Health Care; 2018 Dec; 48(12):321-332. PubMed ID: 30466840
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adolescent use of the monthly contraceptive injection.
    Tuchman LK; Huppert JS; Huang B; Slap GB
    J Pediatr Adolesc Gynecol; 2005 Aug; 18(4):255-60. PubMed ID: 16171729
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reasons for contraceptive discontinuation in women 20-39 years old in New Zealand.
    Colli E; Tong D; Penhallegon R; Parazzini F
    Contraception; 1999 Apr; 59(4):227-31. PubMed ID: 10457866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.